{"product_id":"mrk-swot-analysis","title":"(MRK) Merck \u0026 Co., Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Reference Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Merck \u0026amp; Co., Inc. SWOT Analysis provides a concise, company-specific breakdown of strengths, weaknesses, opportunities, and threats to support research, strategy, investing, or presentations; the content shown here is a real preview of the actual deliverable so you can judge style and depth before buying. Purchase the full version to access the complete ready-to-use analysis and supporting insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeytruda generated $29.5B in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeytruda generated $29.5 billion in 2024 sales, making Merck’s oncology franchise its main profit driver. It is one of the world’s top-selling medicines and gives Merck a deep earnings base that funds R\u0026amp;D. That scale also helps support larger combination-trial spending and new cancer studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGardasil franchise delivered $8.6B in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. leads HPV prevention with Gardasil and Gardasil 9, and the franchise delivered $8.6 billion in 2024 sales. It gives Merck a second major growth pillar beyond oncology and broadens its reach across pediatric, adolescent, and adult immunization markets. That scale makes Gardasil one of Merck’s most important non-oncology assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 core divisions across human and animal health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc.'s two-core-division model spreads risk across human health and Animal Health, so weak demand in one market does not fully hit the company. The Pharmaceuticals unit covers oncology, immunology, virology, cardiovascular disease, diabetes, and vaccines, while Animal Health adds veterinary medicines, vaccines, and digital monitoring tools. That mix gives Merck broader revenue support and more ways to grow. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal customer reach across hospitals, wholesalers, HMOs, and veterinarians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. sells to hospitals, wholesalers, HMOs, and veterinarians, so demand comes from many buyer groups instead of one channel. In 2024, Animal Health sales were about $5.9 billion, showing the reach of both human and animal health markets. That breadth helps reduce exposure to any single payer or customer.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWide channel mix\u003c\/li\u003e\n\u003cli\u003eHuman and animal health\u003c\/li\u003e\n\u003cli\u003eLower buyer concentration risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrategic HIV partnerships with 5 major biopharma companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc.’s HIV alliances with AstraZeneca, Bayer, Eisai, Ridgeback Biotherapeutics, and Gilead Sciences widen its development reach and cut single-partner risk. These deals help support long-acting HIV work, where the commercial prize is large: the global HIV drug market was about $30 billion in 2025, with long-acting regimens gaining share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 biopharma partners\u003c\/li\u003e\n\u003cli\u003eBroader R\u0026amp;D access\u003c\/li\u003e\n\u003cli\u003eStronger launch reach\u003c\/li\u003e\n\u003cli\u003eSupports long-acting HIV pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMerck’s scale also helps it run these programs: it spent $17.9 billion on research and development in 2024, giving it room to back complex, multi-party trials. That depth matters in HIV, where better dosing convenience can improve adherence and drive uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck’s Blockbuster Drugs Power Diverse Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. has two blockbuster engines: Keytruda at $29.5 billion in 2024 sales and Gardasil at $8.6 billion. Animal Health added about $5.9 billion, so the mix is not tied to one market. Merck also spent $17.9 billion on R\u0026amp;D, supporting deep pipelines and new launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda scale\u003c\/td\u003e\n\u003ctd\u003e$29.5B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil growth\u003c\/td\u003e\n\u003ctd\u003e$8.6B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal Health\u003c\/td\u003e\n\u003ctd\u003e$5.9B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D firepower\u003c\/td\u003e\n\u003ctd\u003e$17.9B spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Merck \u0026amp; Co., Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eDelivers a quick Merck SWOT snapshot to simplify strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of Merck sources—industry reports, filings, and datasets—to speed due diligence and validate key financial and market assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy dependence on Keytruda sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeytruda still drives a very large share of Merck \u0026amp; Co., Inc. revenue, with 2025 sales near $29 billion, or about half of total company revenue. That concentration lifts earnings risk if growth slows or pricing weakens. It also leaves Merck \u0026amp; Co., Inc. more exposed to the 2028 loss of exclusivity, which could hit cash flow hard. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGardasil demand has been volatile in China\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. said Gardasil demand in China has swung with channel inventory cuts, which makes this big vaccine market hard to forecast. Gardasil generated about $8.6 billion in 2024 sales, so any China slowdown hits a major non-oncology driver. The volatility also clouds near-term growth visibility and keeps pressure on Merck \u0026amp; Co., Inc.'s vaccine outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimal Health is much smaller than Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. still relies on human pharma: in 2025, Pharmaceutical sales were about $57 billion, while Animal Health was roughly $6 billion, or near 10% of revenue. That smaller scale means the animal unit helps, but it cannot offset big pharma setbacks like Keytruda patent risk or launch swings. So diversification benefits stay limited when the core business is hit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D spend keeps cost pressure elevated\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. spent $17.9 billion on R\u0026amp;D in 2024, about 28% of revenue, and that kind of load stays a weakness when launches lag. It has to fund big trials, FDA and global filings, and life-cycle work across many programs, so margins can stay under pressure until new drugs scale. The bigger risk is clear: every weak launch makes the next blockbuster harder to replace.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D was $17.9 billion in 2024\u003c\/li\u003e\n\u003cli\u003eAbout 28% of revenue\u003c\/li\u003e\n\u003cli\u003eLarge trials raise fixed costs\u003c\/li\u003e\n\u003cli\u003eWeak launches hurt margins\u003c\/li\u003e\n\u003cli\u003ePipeline must replace blockbusters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline replacement risk remains visible after Keytruda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. still faces pipeline-replacement risk because Keytruda generated about $29.5 billion in 2025 sales, making it hard for any one late-stage drug to fill the gap if growth slows after patent loss. Even with several Phase 3 programs, no single asset can match Keytruda’s scale alone, so Merck needs multiple launches to carry the next earnings cycle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKeytruda is still the earnings anchor.\u003c\/li\u003e\n\u003cli\u003eOne drug cannot replace $29.5 billion.\u003c\/li\u003e\n\u003cli\u003eNew launches must execute well.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck’s Keytruda Dependence Puts Growth and Margins at Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. remains exposed to Keytruda concentration risk: 2025 sales were about $29.5 billion, near half of revenue, so any slowdown or 2028 loss of exclusivity could hit cash flow hard. Gardasil added another swing factor, with China inventory cuts hurting visibility. Heavy R\u0026amp;D also weighs on margins, with $17.9 billion spent in 2024, about 28% of revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda dependence\u003c\/td\u003e\n\u003ctd\u003e$29.5B sales in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil volatility\u003c\/td\u003e\n\u003ctd\u003eChina demand swings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D burden\u003c\/td\u003e\n\u003ctd\u003e$17.9B in 2024, 28% of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMerck \u0026amp; Co., Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is a real excerpt from the complete Merck \u0026amp; Co., Inc. SWOT analysis document—you’re viewing the exact content included in the downloadable file; purchase unlocks the full, editable report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeytruda still has room for label expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeytruda already has 40-plus approved uses across cancer types and settings, and Merck \u0026amp; Co., Inc. is still adding combo and earlier-stage labels. In 2025, Keytruda delivered about $29.5 billion in sales, so each new approval can extend its revenue run before loss of exclusivity. That gives Merck \u0026amp; Co., Inc. a strong tailwind in lung, bladder, and perioperative cancers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-acting HIV therapies could open a new franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. is pushing long-acting HIV regimens, aiming at a 39.9 million-person global market in 2023. Monthly or less frequent dosing can improve adherence and make treatment easier than daily pills, which is key in chronic care. If Merck wins here, it could build a new specialty-care franchise with recurring revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWINREVAIR launch adds a new growth driver\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWINREVAIR gives Merck a fresh specialty launch in pulmonary arterial hypertension, a niche with high unmet need. With Merck at $64.2 billion in 2024 sales and Keytruda at $29.5 billion, early WINREVAIR uptake can build a new revenue stream and trim dependence on oncology and vaccines. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAnimal Health digital tools can deepen recurring sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. can turn Animal Health traceability, identification, and monitoring tools into repeat sales because they need tags, readers, software updates, and service support over time. This fits the shift to data-driven livestock management, where producers want live herd data, faster trace-back, and lower loss risk.\u003c\/p\u003e\n\u003cp\u003eThese products act more like software than one-off hardware, so they can lift recurring revenue and deepen customer ties. In a market where livestock ID and traceability are becoming standard practice in many export chains, the sticky service model is a real edge for Merck \u0026amp; Co., Inc.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat sales from tags and software\u003c\/li\u003e\n\u003cli\u003eStickier service and support revenue\u003c\/li\u003e\n\u003cli\u003eBetter fit for data-led farming\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVaccines can expand further in adult and emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck already sells vaccines across pediatric, adolescent, and adult use, so uptake in underpenetrated emerging markets can add volume over time. That matters because vaccine demand is sticky, and new public-health pushes can support long-term growth even as the U.S. adult market matures. Merck’s vaccine franchise is still a multibillion-dollar business, so small share gains abroad can move revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdult use can widen the addressable market.\u003c\/li\u003e\n\u003cli\u003eEmerging markets can lift unit volume.\u003c\/li\u003e\n\u003cli\u003ePublic-health demand can support steady growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck’s Growth Engine: Keytruda, HIV Shots, and New Specialty Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. can still grow Keytruda by adding new labels and moving into earlier-stage cancer, and 2025 sales were about $29.5 billion. Long-acting HIV shots could open a large chronic-care market, where monthly dosing may beat daily pills. WINREVAIR adds a new specialty line, while Animal Health traceability tools can lift repeat sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportun\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003e$29.5B 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV\u003c\/td\u003e\n\u003ctd\u003e39.9M global 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeytruda faces biosimilar and patent-expiry risk in 2028\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeytruda is Merck \u0026amp; Co., Inc.'s biggest risk: 2024 sales were about $29.5 billion, nearly half of company revenue. Its core U.S. patent wall starts in 2028, and biosimilar entry could quickly cut price and share. That would hit Merck \u0026amp; Co., Inc.'s revenue and operating profit hard.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing pressure from governments and pharmacy buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck faces steady pricing pressure because U.S. payers, PBMs, hospitals, and governments keep pushing down drug costs in a highly regulated market. In 2024, Merck generated $64.2 billion in revenue, with Keytruda at $29.5 billion, so even small rebate or price cuts can hit a large sales base. That pressure can squeeze margins across both pharma and vaccines, especially when buyers demand more discounts and tighter access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory setbacks can delay pipeline value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLate-stage trials are a binary risk: one FDA or EMA setback can erase years of R\u0026amp;D spend and delay value from Merck \u0026amp; Co., Inc.'s pipeline. That matters because Keytruda drove about $29.5 billion of Merck \u0026amp; Co., Inc.'s $64.2 billion 2024 revenue, so new blockbusters are needed fast. A single rejection can also hit launch timing, pricing, and peak-sales assumptions all at once.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompetitors remain strong in oncology and vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBig rivals still pressure Merck \u0026amp; Co., Inc. in oncology and vaccines: Keytruda generated about $29.5 billion in 2024 sales, and Gardasil about $8.6 billion, so even small share losses matter. New launches from Roche, Bristol Myers Squibb, AstraZeneca, Pfizer, and GSK can slow gains and shorten product life cycles. That also raises the cost of defending two of Merck \u0026amp; Co., Inc.'s biggest franchises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eKeytruda scale makes defense costly.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eGardasil faces tougher vaccine rivals.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eLaunches can erode pricing power.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chain and geopolitical disruption can hit global sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. runs a global manufacturing and distribution network, so trade tension, tariffs, or port delays can slow product flow and hit sales fast. In 2025, supply shocks still mattered because a single delay can affect both human health products and animal health shipments.\u003c\/p\u003e\n\u003cp\u003eRegional outbreaks can also lift or cut demand for vaccines and animal health products, while import rules can block cross-border supply. That makes Merck \u0026amp; Co., Inc. more exposed when governments tighten rules or logistics costs jump.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal supply chains add disruption risk.\u003c\/li\u003e\n\u003cli\u003eTariffs can raise landed costs.\u003c\/li\u003e\n\u003cli\u003eOutbreaks can swing vaccine demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck’s Keytruda cliff and pricing pressure threaten margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKeytruda is still Merck \u0026amp; Co., Inc.'s biggest threat: 2024 sales were about $29.5 billion, and U.S. patent loss from 2028 could bring fast biosimilar erosion. Merck \u0026amp; Co., Inc. also faces nonstop pricing pressure from payers and governments, which can cut margins across a $64.2 billion revenue base. R\u0026amp;D and regulatory setbacks can wipe out years of spend, while rivals in oncology and vaccines keep pressing share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda patent cliff\u003c\/td\u003e\n\u003ctd\u003e~$29.5B 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePricing pressure\u003c\/td\u003e\n\u003ctd\u003e$64.2B 2024 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191786512649,"sku":"mrk-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mrk-swot-analysis.webp?v=1783677063","url":"https:\/\/dcfanalyst.com\/products\/mrk-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}